Clinical Trial Supply and Logistics Market (By Service: Logistics & Distribution, Storage & Retention, Packaging, Labeling, and Blinding, Manufacturing, Comparator Sourcing, Others; By Phase: Phase I, Phase II, Phase III, Phase IV; By End-user: Pharmaceuticals, Biologicals, Medical Device; By Therapeutic Area: Oncology, Cardiovascular Diseases, Respiratory Diseases, CNS and Mental Disorders, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Clinical Trial Supply and Logistics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Clinical Trial Supply and Logistics Market, by Service, 2023-2032
8.1.1. Logistics & Distribution
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Storage & Retention
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Packaging, Labeling, and Blinding
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Manufacturing
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Comparator Sourcing
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2020-2032)
9.1. Clinical Trial Supply and Logistics Market, by Phase, 2023-2032
9.1.1. Phase I
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Phase II
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Phase III
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Phase IV
9.1.4.1. Market Revenue and Forecast (2020-2032)
10.1. Clinical Trial Supply and Logistics Market, by End-user, 2023-2032
10.1.1. Pharmaceuticals
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Biologicals
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Medical Device
10.1.3.1. Market Revenue and Forecast (2020-2032)
11.1. Clinical Trial Supply and Logistics Market, by Therapeutic Area, 2023-2032
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Cardiovascular Diseases
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Respiratory Diseases
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. CNS and Mental Disorders
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Others
11.1.5.1. Market Revenue and Forecast (2020-2032)
12.1. North America
12.1.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.2. Market Revenue and Forecast, by Phase (2020-2032)
12.1.3. Market Revenue and Forecast, by End-user (2020-2032)
12.1.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Phase (2020-2032)
12.1.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.1.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Phase (2020-2032)
12.1.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.1.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.2. Market Revenue and Forecast, by Phase (2020-2032)
12.2.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Phase (2020-2032)
12.2.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Phase (2020-2032)
12.2.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Phase (2020-2032)
12.2.7.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Phase (2020-2032)
12.2.8.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.2. Market Revenue and Forecast, by Phase (2020-2032)
12.3.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Phase (2020-2032)
12.3.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Phase (2020-2032)
12.3.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Phase (2020-2032)
12.3.7.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Phase (2020-2032)
12.3.8.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.2. Market Revenue and Forecast, by Phase (2020-2032)
12.4.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Phase (2020-2032)
12.4.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Phase (2020-2032)
12.4.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Phase (2020-2032)
12.4.7.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Phase (2020-2032)
12.4.8.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.2. Market Revenue and Forecast, by Phase (2020-2032)
12.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Phase (2020-2032)
12.5.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.5.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Phase (2020-2032)
12.5.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.5.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
13.1. Almac Group
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. DHL
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Parexel
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Thermo Fisher Scientific (Patheon)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Marken
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Piramal Pharma Solutions
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. UDG Healthcare
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Catalent, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. FedEx
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Movianto
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample